Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TERT | O14746 | 3/20 | 0.38 |
| ▸ | DHODH | Q02127 | 1/20 | 0.35 |
| ▸ | TOP1 | P11387 | 1/20 | 0.34 |
| ▸ | CYCS | P99999 | 2/20 | 0.33 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19289802 | 0.89 | HSP90AA1 (0.36) | TERTDHODHTOP1MAPK14 | |
| SCHEMBL24221269 | 0.89 | DHODH (0.38) | TERTDHODHTOP1CYCSMEN1 | |
| SCHEMBL19296902 | 0.89 | DHODH (0.36) | TERTDHODHTOP1CYCS | |
| SCHEMBL19855754 | 0.88 | TERT (0.41) | TERTTOP1CYCSMEN1KMT2A | |
| SCHEMBL17651811 | 0.84 | TOP1 (0.43) | TERTDHODHTOP1CYCS | |
| SCHEMBL17651778 | 0.84 | TOP1 (0.43) | TERTDHODHTOP1CYCS | |
| SCHEMBL19296891 | 0.84 | ABCG2 (0.37) | DHODHTOP1CYCS | |
| SCHEMBL19289582 | 0.84 | DHODH (0.33) | DHODHTOP1CYCSMAPK14 | |
| SCHEMBL19278958 | 0.84 | DHODH (0.33) | TERTDHODHTOP1CYCSMAPK14 | |
| SCHEMBL31310006 | 0.84 | DHODH (0.33) | TERTDHODHTOP1CYCSMAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3201201-B1 | SPECIFICALLY MESO-SUBSTITUTED PORPHYRINS AND CHLORINS FOR PHOTODYNAMIC THERAPY | BIOLITEC UNTERNEHMENSBETEILIGUNGS II AG (AT) | 2022-01-26 | — | — | EP | disclosed |
| US-10456375-B2 | Specifically meso-substituted porphyrins and chlorins for photodynamic therapy | BIOLITEC UNTERNEHMENSBETEILIGUNGS II AG (AT) | 2019-10-29 | — | — | US | disclosed |
| US-20180036284-A1 | SPECIFICALLY meso-SUBSTITUTED PORPHYRINS AND CHLORINS FOR PHOTODYNAMIC THERAPY | BIOLITEC UNTERNEHMENSBETEILIGUNGS II AG (AT) | 2018-02-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180036284-A1 | SPECIFICALLY meso-SUBSTITUTED PORPHYRINS AND CHLORINS FOR PHOTODYNAMIC THERAPY | DHPS, DDT, PPOX | TERT 1760/4885DHODH 27/4885TOP1 2038/4885 |
| US-10456375-B2 | Specifically meso-substituted porphyrins and chlorins for photodynamic therapy | DHPS, DDT, PPOX | TERT 1760/4885DHODH 27/4885TOP1 2038/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.